Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2024-02-29
Target enrollment:
Participant gender:
Summary
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1
antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer
patients, in order to find a better therapy strategy for pancreatic cancer patients.